Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9676236 | 0.82 | NPC1 (0.51) | METBRPF1KCNH2NR3C2KDM1A | |
| SCHEMBL17442627 | 0.78 | NPBWR1 (0.41) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26352480 | 0.78 | RAB9A (0.53) | METBRPF1KCNH2NR3C2TP53 | |
| SCHEMBL8569802 | 0.77 | MET (0.45) | METBRPF1KCNH2NR3C2TP53 | |
| SCHEMBL17375009 | 0.76 | BRPF1 (0.46) | METBRPF1KCNH2MAPK10CA1 | |
| SCHEMBL695033 | 0.76 | BRPF1 (0.51) | BRPF1NR3C2CA1CA2ALDH1A1 | |
| SCHEMBL26613503 | 0.76 | LMNA (0.58) | METKCNH2NR3C2TP53KDM1A | |
| SCHEMBL171701 | 0.75 | CA1 (0.67) | BRPF1NR3C2CA1CA2ALDH1A1 | |
| SCHEMBL30186176 | 0.75 | CA1 (0.67) | BRPF1NR3C2CA1CA2ALDH1A1 | |
| SCHEMBL29625693 | 0.75 | CA1 (0.67) | BRPF1NR3C2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188104-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | MET 4151/4885BRPF1 2988/4885KCNH2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.